YCBD
cbdMD, Inc.1.4300
+0.2300+19.2%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q1 '26
Light Q&A adds integration details
Q&A stayed light, largely reaffirming prepared remarks with minor color on Bluebird integration. Management will run Bluebird as a separate brand for its distinct customers, folding in a small team while tweaking SKUs and supply chain for growth opportunities. Oasis seltzers contribute modestly now but should ramp this year—no specifics disclosed. Brands stay separate. No walk-backs or fresh guidance surfaced, leaving investors watching integration synergies and beverage traction amid regulatory haze.
Key Stats
Market Cap
12.75MP/E (TTM)
2.80Basic EPS (TTM)
0.51Dividend Yield
0%Recent Filings
8-K
Shareholders approve equity plan, issuances
cbdMD shareholders approved the 2025 Equity Compensation Plan on March 30, 2026, reserving 891,316 shares initially and triggering issuance of 445,000 restricted shares to CEO/CFO T. Ronan Kennedy as employment incentive. All seven directors elected; Cherry Bekaert ratified as auditors. Reverse split and equity issuances for Series B/C preferred and ELOC greenlit despite dilution risks.
10-Q
Q1 FY2026 results
cbdMD posted Q1 FY2026 net sales of $5.0M, down 1.9% y/y from $5.1M, with gross margin slipping to 59.8% from 66.5% on higher warehouse costs and wholesale mix shift, while operating expenses fell 5.7% to $3.3M. Operating loss widened to $(286K) from $(86K); net loss $(283K) aligned closely after minor interest income, but common shareholders absorbed $(325K) post-$41K preferred dividends. Cash climbed to $3.4M (up ~$1.1M q/q) via $2.1M Series C preferred raise, despite $812K operating cash burn; no debt remains. Closed Bluebird Botanicals acquisition in Jan 2026 for 425K restricted shares plus up to 525K earnout shares. E-commerce drove 71.8% of sales. Preferred dilution looms large.
8-K
cbdMD acquires Bluebird Botanicals
cbdMD closed its asset purchase of Gaia Botanicals' Bluebird Botanicals CBD brand, website, inventory, and contracts on January 12, 2026, issuing 425,000 restricted shares upfront plus up to 525,000 earnout shares tied to $2M-$2.9M net revenue in year one. Shares face 180-day lockup, then 125,000 quarterly dribble-out. cbdMD commits $90,000 quarterly marketing. Earnout hinges on performance.
10-K
FY2025 results
cbdMD held FY2025 revenue steady at $19.2M, down slightly from $19.5M in FY2024, while slashing GAAP operating loss to $2.2M from $3.3M through cost cuts and portfolio tweaks—yet Q4 sales accelerated 4% y/y to $4.7M, fueled by wholesale gains and Oasis THC beverages expanding across Southeast retailers. Gross margins expanded to 63% annually (62.4% adjusted) and 58.8% in Q4 from 53.9% prior year, despite product mix shifts to lower-margin gummies and drinks. E-commerce stabilized at 77% of sales as marketing ramps; cash hit $2.2M with $3.1M working capital after Series A conversion boosted equity. Q4 built momentum into early FY2026, but federal hemp rules loom large.
8-K
Regains NYSE compliance
cbdMD regained NYSE American listing compliance on December 5, 2025, resolving prior deficiencies under Sections 1003(a)(i) and (ii). The .BC indicator vanished at open on December 8. Balance sheet strengthened via May preferred share conversion and September capital raise. Normal monitoring resumes.
IPO
Website
Employees
Sector
Industry
CBDL
CBD Life Sciences Inc.
0.00+0.00
CBDY
Target Group Inc.
0.00+0.00
CBSTF
THE CANNABIST COMPANY HOLDINGS
0.10+0.03
CRLBF
Cresco Labs Inc.
1.75+0.45
CURLF
Curaleaf Holdings, Inc.
4.53+0.85
CWBHF
Charlotte's Web Holdings Inc.
0.15+0.00
LEEEF
LEEF BRANDS INC
0.22+0.02
MRMD
MariMed Inc.
0.12+0.01
NXGB
NxGen Brands Inc.
0.00-0.00
TLRY
Tilray Brands, Inc.
13.94+3.01